title: Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005.
abstract: BACKGROUND
  There are limited data on the proportion who have been exposed to vaccine-type human papillomavirus (HPV) among women attending sexually transmitted disease (STD) clinics; this information could inform the potential benefits of HPV vaccination for women attending this venue.
  
  
  METHODS
  Human papillomavirus surveillance was conducted in STD clinics in Baltimore, MD; Boston, MA; Denver, CO; Los Angeles, CA; and Seattle, WA, among women receiving cervical cancer screening from January 2003 to December 2005. The women had specimens collected for cervical cytology HPV testing by L1 consensus polymerase chain reaction testing and serologic assessment for HPV 6, 11, 16, and 18 using the competitive Luminex immunoassay. Results from 880 women with adequate specimens were included. Women were HPV naïve if they were both HPV DNA negative and seronegative for a specific HPV type.
  
  
  RESULTS
  One hundred seventy women (19.3%) had HPV 16, 18, 6, or 11 DNA, and 418 (47.5%) were HPV 16, 18, 6, or 11 seropositive. Four hundred ten (46.6%) women were naïve to all 4 types, 570 (64.8%) were naïve to both HPV 16 and 18, and 545 (61.9%) were naïve to both HPV 6 and 11. Almost all (99.3%) women were naïve to at least 1 vaccine HPV type.
  
  
  CONCLUSIONS
  Almost half of young women age eligible for HPV vaccine and attending STD clinics were naïve to all 4 HPV types, and more than half were naïve to both HPV 16 and 18. This assessment suggests that most young women attending this venue might benefit from HPV vaccination.
authors: From the *Centers for Disease Control and Prevention, Atlanta, GA; †Division of STD Prevention, Massachusetts Department of Public Health, Boston, MA; ‡Johns Hopkins University School of Medicine, Baltimore, MD; §STD Program, County of Los Angeles Department of Health Services, Los Angeles, CA; ¶Denver Public Health, Denver, CO; ∥University of Washington, Seattle, WA; and **GAVI, Geneva, Switzerland.
authors: Eileen F
authors: EF
authors: Dunne
authors: Elaine W
authors: EW
authors: Flagg
authors: Elizabeth R
authors: ER
authors: Unger
authors: Kathy
authors: K
authors: Hsu
authors: Khalil
authors: K
authors: Ghanen
authors: Peter
authors: P
authors: Kerndt
authors: Judy C
authors: JC
authors: Shlay
authors: Laura A
authors: LA
authors: Koutsky
authors: Deblina S
authors: DS
authors: Datta
authors: Gitika
authors: G
authors: Panicker
authors: Akbar
authors: A
authors: Zaidi
authors: Hillard
authors: H
authors: Weinstock
authors: Lauri E
authors: LE
authors: Markowitz
mesh_terms: D000293:Adolescent; D015142:Baltimore; D001900:Boston; D002648:Child; D003120:Colorado; D003362:Cost-Benefit Analysis; D004279:DNA, Viral / Q000276:immunology*; D005260:Female; D006801:Humans; D017589:Immunization Programs / Q000458:organization & administration*; D015141:Los Angeles; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D018571:Sentinel Surveillance; D012725:Sexual Behavior; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination; D014861:Washington; D055815:Young Adult
chemical_list: D004279:DNA, Viral; D053918:Papillomavirus Vaccines